<DOC>
	<DOCNO>NCT01111175</DOCNO>
	<brief_summary>Patients metastatic locally recurrent triple negative breast cancer ( TNBC ) schedule medically indicated surgical biopsy resection disease identify . Fresh/frozen tissue collect undergo comprehensive molecular evaluation NextGen sequencing . TGEN 's clonal genomics analysis apply analysis identify prioritize mutate target . Therapeutic option , base genetic profile patient 's tumor , discussed appropriate molecularly-selected agent recommend Study Investigator ( ) ( SI ) treat oncologist treatment patient . This open-label , pilot trial . Patients metastatic locally recurrent TNBC schedule medically indicated surgical biopsy resection enrol therapeutic option , base genetic profile patient 's tumor , discuss patient . Time-to-progression ( TTP ) patient follow select therapy primary objective compare TTP ( ) recent prior therapy . A 30 % increase TTP molecularly-targeted agent compare TTP immediate prior therapy consider evidence clinical benefit select therapy . The secondary endpoint best response molecularly-selected therapy , overall survival ( OS ) genetic mutation evaluation metastatic ( locally recurrent ) TNBC . The study design demonstrate collection analysis tumor sample feasible .</brief_summary>
	<brief_title>Triple Negative Breast Cancer Biomarker Study</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<criteria>Has metastatic locally recurrent triple negative breast cancer schedule medically indicated surgical biopsy resection disease Will measurable evaluable ( nonmeasurable ) disease per RECIST v 1.1 ( see Section 10 ) present surgical biopsy/resection . Note : following surgical resection , tumor sample find inadequate comprehensive molecular analysis , patient deem ineligible replace . Has receive least 1 prior chemotherapeutic regimen metastatic locally recurrent TNBC prior initiate molecularlyselected therapy . There limit prior therapy TNBC . Note : We strongly recommend hold intervene therapy possible time biopsy completion sequence change cancer selective pressure treatment , sequence result reflective current cancer . Is least 18 year age Has expect survival least 6 month , estimate treat oncologist Has plan surgical resection ( indicated medical care patient ) yield minimum fresh/frozen tumor sample 1 cm x 1 cm x 1 cm ( ~300 mg ) available molecular profiling analysis . Is agreeable blood sample ( 1020 mL ) drawn analyze compare normal genetic profile tumor sample Has sign recent Patient Informed Consent Form Has sign Patient Authorization Form Has breast cancer metastatic locally recurrent TNBC . Note : surgical resection recurrent TNBC render patient `` evidence disease '' ( NED ) . NED patient ineligible replace . Has history heart disease , condition would prevent treatment standard chemotherapeutic agent Has evidence central nervous system ( CNS ) involvement progress require radiation , resection steroid therapy Has serious uncontrolled intercurrent medical psychiatric illness , include serious infection Is pregnant nurse woman Is unable comply requirement study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Locally recurrent breast cancer</keyword>
</DOC>